ImmuNext Enters Into a Strategic Partnership With Janssen Pharmaceutica N.V. to Develop Novel Immunotherapies for the Treatment of Cancer

September 5, 2012 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LEBANON, N.H.--(BUSINESS WIRE)--ImmuNext, Inc., today announced that it has entered into an agreement with Janssen Biotech, Inc., focused on the development of novel therapeutics that modulate the immune system for the treatment of cancer.

Twitter
LinkedIn
Facebook
Email
Print

Alliances